Dajun Yang, Ascentage Pharma CEO
January 21, 2025 10:11 AM EST
Financing
China

As­cen­t­age es­ti­mates $133M in pro­ceeds as it plans Nas­daq dual list­ing

Kyle LaHucik

Senior Reporter

As­cen­t­age Phar­ma’s plans for a dual list­ing in the US could load its cof­fers with about $133 mil­lion in net pro­ceeds, the com­mer­cial drug­mak­er said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site

Re­newed mifepri­s­tone fight will be ear­ly test of Trump’s abor­tion stance in his sec­ond term

Sion­na and Odyssey end JPM week with IPO fil­ings

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times